Reference : Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive rela...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients
Vandemeulebroucke, E. [ > > ]
Keymeulen, B. [ > > ]
Decochez, K. [ > > ]
Weets, I. [ > > ]
De Block, C. [ > > ]
Féry, F. [ > > ]
Van de Velde, U. [ > > ]
Vermeulen [ > > ]
De Pauw, P. [ > > ]
Mathieu, C. [ > > ]
Pipeleers, D. G. [ > > ]
Paquot, Nicolas mailto [Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Gorus, F. K. [ > > ]
Springer Verlag
Yes (verified by ORBi)
[en] Autoantibodies/*blood C-Peptide/blood ; C-Peptide/blood MH - Diabetes Mellitus/*epidemiology/genetics MH - Diabetes Mellitus, Type 1/genetics/immunology MH - MH - Risk Assessment ; Reference Values ; Medical History Taking ; Insulin/blood ; Hyperglycemia ; Humans ; HLA-DQ Antigens/genetics ; Glucose Clamp Technique ; diabtes mellitus Type 1/genetics/immunology
[en] AIMS/HYPOTHESIS: The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+) FDRs) of type 1 diabetic patients.

METHODS: Hyperglycaemic clamps were performed in 17 non-diabetic IA-2A(+) FDRs aged 14 to 33 years and in 21 matched healthy volunteers (HVs). Insulin and C-peptide responses were measured during the first (5-10 min) and second (120-150 min) release phase, and after glucagon injection (150-160 min). Clamp-induced C-peptide release was compared with C-peptide release during OGTT.

RESULTS: Seven (41%) FDRs developed diabetes 3-63 months after their initial clamp test. In all phases they had lower C-peptide responses than non-progressors (p < 0.05) and HVs (p < 0.002). All five FDRs with low first-phase release also had low second-phase release and developed diabetes 3-21 months later. Two of seven FDRs with normal first-phase but low second-phase release developed diabetes after 34 and 63 months, respectively. None of the five FDRs with normal C-peptide responses in all test phases has developed diabetes so far (follow-up 56 to 99 months). OGTT-induced C-peptide release also tended to be lower in progressors than in non-progressors or HVs, but there was less overlap in results between progressors and the other groups using the clamp.

CONCLUSIONS/INTERPRETATION: Clamp-derived functional variables stratify risk of diabetes in IA-2A(+) FDRs and may more consistently identify progressors than OGTT-derived variables. A low first-phase C-peptide response specifically predicts impending diabetes while a low second-phase response may reflect an earlier disease stage
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
hyperglycaemic clamp ocr.pdfAuthor postprint239.63 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.